JENNIFER WARGO to Animals
This is a "connection" page, showing publications JENNIFER WARGO has written about Animals.
Connection Strength
0.843
-
Engineering immunity: bacterial delivery of cancer neoantigen vaccines. Trends Immunol. 2024 Dec; 45(12):931-933.
Score: 0.042
-
From bugs to drugs: Bacterial 3-IAA enhances efficacy of chemotherapy in pancreatic cancer. Cell Rep Med. 2023 05 16; 4(5):101039.
Score: 0.038
-
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640.
Score: 0.035
-
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology. 2021; 10(1):1992880.
Score: 0.034
-
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021 10 14; 184(21):5309-5337.
Score: 0.034
-
Gut Microbiome Modulates Response to Cancer Immunotherapy. Dig Dis Sci. 2020 03; 65(3):885-896.
Score: 0.030
-
The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View. Trends Cancer. 2020 03; 6(3):192-204.
Score: 0.030
-
The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies. Surg Oncol Clin N Am. 2019 07; 28(3):369-386.
Score: 0.029
-
The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy. Trends Immunol. 2018 11; 39(11):900-920.
Score: 0.028
-
Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy. Front Immunol. 2018; 9:946.
Score: 0.027
-
Universes collide: combining immunotherapy with targeted therapy for cancer. Cancer Discov. 2014 Dec; 4(12):1377-86.
Score: 0.021
-
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014 Jul; 2(7):643-54.
Score: 0.020
-
Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. Cancer Gene Ther. 2005 Jun; 12(6):516-27.
Score: 0.011
-
Inflammation Mediated by Gut Microbiome Alterations Promotes Lung Cancer Development and an Immunosuppressed Tumor Microenvironment. Cancer Immunol Res. 2024 Dec 03; 12(12):1736-1752.
Score: 0.011
-
Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease. Cell Host Microbe. 2024 Sep 11; 32(9):1621-1636.e6.
Score: 0.010
-
Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma. Cancer Immunol Res. 2023 05 03; 11(5):558-569.
Score: 0.009
-
Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance. Nature. 2023 05; 617(7960):377-385.
Score: 0.009
-
Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci Transl Med. 2022 11 16; 14(671):eabo3445.
Score: 0.009
-
Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration. J Exp Med. 2023 02 06; 220(2).
Score: 0.009
-
Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease. Cell. 2022 09 29; 185(20):3705-3719.e14.
Score: 0.009
-
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.
Score: 0.009
-
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022 05 09; 40(5):509-523.e6.
Score: 0.009
-
Coenzyme A fuels T?cell anti-tumor immunity. Cell Metab. 2021 12 07; 33(12):2415-2427.e6.
Score: 0.009
-
Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell. 2021 10 14; 184(21):5338-5356.e21.
Score: 0.009
-
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.
Score: 0.008
-
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nat Commun. 2021 01 12; 12(1):346.
Score: 0.008
-
Considerations for designing preclinical cancer immune nanomedicine studies. Nat Nanotechnol. 2021 01; 16(1):6-15.
Score: 0.008
-
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunol Res. 2020 11; 8(11):1365-1380.
Score: 0.008
-
Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells. J Exp Med. 2020 08 03; 217(8).
Score: 0.008
-
Can we harness the microbiota to enhance the efficacy of cancer immunotherapy? Nat Rev Immunol. 2020 09; 20(9):522-528.
Score: 0.008
-
Uncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review. Semin Hematol. 2020 01; 57(1):13-18.
Score: 0.008
-
Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma. Nat Commun. 2020 02 12; 11(1):853.
Score: 0.008
-
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc Natl Acad Sci U S A. 2019 11 05; 116(45):22699-22709.
Score: 0.007
-
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res. 2019 Oct; 29(10):846-861.
Score: 0.007
-
Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019 08 08; 178(4):795-806.e12.
Score: 0.007
-
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat Immunol. 2019 09; 20(9):1231-1243.
Score: 0.007
-
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov. 2019 05; 9(5):628-645.
Score: 0.007
-
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018 11 01; 175(4):998-1013.e20.
Score: 0.007
-
Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility. Cancer Discov. 2019 01; 9(1):64-81.
Score: 0.007
-
Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma. Cancer Discov. 2018 11; 8(11):1366-1375.
Score: 0.007
-
A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov. 2018 05; 8(5):556-567.
Score: 0.007
-
Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Rep. 2017 Nov 14; 21(7):1936-1952.
Score: 0.006
-
A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Rep. 2017 Nov 14; 21(7):1953-1967.
Score: 0.006
-
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 01 05; 359(6371):97-103.
Score: 0.006
-
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017 09 15; 357(6356):1156-1160.
Score: 0.006
-
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell. 2017 Sep 07; 170(6):1120-1133.e17.
Score: 0.006
-
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Mol Med. 2017 08; 9(8):1011-1029.
Score: 0.006
-
Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discov. 2017 08; 7(8):832-851.
Score: 0.006
-
An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. J Exp Med. 2017 06 05; 214(6):1691-1710.
Score: 0.006
-
Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. Clin Cancer Res. 2017 Aug 15; 23(16):4680-4692.
Score: 0.006
-
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555.
Score: 0.006
-
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017 02 09; 168(4):707-723.
Score: 0.006
-
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med. 2016 11 15; 14(1):313.
Score: 0.006
-
Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016 Oct 06; 167(2):397-404.e9.
Score: 0.006
-
Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. Mol Cancer Ther. 2016 10; 15(10):2442-2454.
Score: 0.006
-
sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016 Apr 14; 532(7598):250-4.
Score: 0.006
-
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest. 2016 05 02; 126(5):1834-56.
Score: 0.006
-
Targeted Therapies Combined With Immune Checkpoint Therapy. Cancer J. 2016 Mar-Apr; 22(2):138-46.
Score: 0.006
-
Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice. Oncotarget. 2016 Feb 09; 7(6):6448-59.
Score: 0.006
-
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
Score: 0.006
-
Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS One. 2015; 10(10):e0140310.
Score: 0.006
-
Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene. 2016 Mar 10; 35(10):1225-35.
Score: 0.005
-
Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Rep. 2015 Jun 09; 11(9):1458-73.
Score: 0.005
-
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest. 2015 Apr; 125(4):1459-70.
Score: 0.005
-
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015 Mar; 47(3):250-6.
Score: 0.005
-
YAP in MAPK pathway targeted therapy resistance. Cell Cycle. 2015; 14(12):1765-6.
Score: 0.005
-
EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discov. 2015 Mar; 5(3):274-87.
Score: 0.005
-
Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal. 2014 12 23; 7(357):ra121.
Score: 0.005
-
The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFa. Cancer Discov. 2014 Oct; 4(10):1214-1229.
Score: 0.005
-
Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol. 2014 Nov 01; 193(9):4722-31.
Score: 0.005
-
Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One. 2014; 9(7):e101286.
Score: 0.005
-
A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression. Thyroid. 2014 Aug; 24(8):1241-50.
Score: 0.005
-
PDGFRa up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget. 2014 Apr 15; 5(7):1926-41.
Score: 0.005
-
Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. 2013 Dec; 3(12):1378-93.
Score: 0.005
-
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med. 2013 Jul 31; 5(196):196ra98.
Score: 0.005
-
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013 Jan 15; 19(2):393-403.
Score: 0.005
-
Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 2013 Mar; 3(3):338-49.
Score: 0.005
-
An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature. 2012 Nov 15; 491(7424):449-53.
Score: 0.005
-
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012 Oct; 18(10):1503-10.
Score: 0.005
-
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012 Mar; 2(3):227-35.
Score: 0.004
-
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011 Nov 23; 480(7377):387-90.
Score: 0.004
-
A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol. 2011 Jan 15; 186(2):685-96.
Score: 0.004
-
Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J Immunol. 2010 Jun 01; 184(11):5988-98.
Score: 0.004
-
Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells. J Immunol. 2004 Apr 15; 172(8):4762-9.
Score: 0.003